Phosphodiesterase 3 Inhibitors

Compounds that specifically inhibit PHOSPHODIESTERASE 3.

Also Known As:

PDE-3 Inhibitors; PDE3 Inhibitors; Phosphodiesterase Type 3 Inhibitors; 3 Inhibitor, Phosphodiesterase; Inhibitor, PDE3; Inhibitor, Phosphodiesterase 3; Inhibitors, PDE-3; Inhibitors, PDE3; Inhibitors, Phosphodiesterase 3; PDE 3 Inhibitors; PDE3 Inhibitor; Phosphodiesterase 3 Inhibitor; Phosphodiesterase Type 3 Inhibitor

Networked: 137 relevant articles (12 outcomes, 19 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Enzyme Inhibitors: 1659
      - Phosphodiesterase Inhibitors: 1071
        Phosphodiesterase 3 Inhibitors: 137

Experts

1.	Yoshida, Hideo: 5 articles (02/2022 - 03/2011)
2.	Movsesian, Matthew: 5 articles (01/2019 - 01/2015)
3.	Itoh, Shinsuke: 4 articles (02/2022 - 01/2012)
4.	Sadeghian, Hamid: 4 articles (02/2015 - 01/2008)
5.	Ito, Hideki: 3 articles (01/2017 - 01/2007)
6.	Sahu, Abhiram: 3 articles (01/2017 - 08/2002)
7.	Olesen, Jes: 3 articles (11/2014 - 04/2004)
8.	Yan, Chen: 3 articles (11/2013 - 05/2005)
9.	Tanabe, Sohei: 3 articles (08/2012 - 01/2012)
10.	Parsaee, Heydar: 3 articles (01/2010 - 01/2008)

Related Diseases

1.	Heart Failure 01/01/2023 - "Our findings reveal a mechanism that explains the negative long-term clinical outcome observed in patients with heart failure treated with PDE3 inhibitors." 06/01/2020 - "Phosphodiesterase-3 (PDE3) inhibitors are widely used among patients with congestive heart failure (CHF). " 01/01/2019 - "PDE3 inhibitors (PDE3i) are used for short-term treatment of refractory heart failure (HF), but do not produce uniform long-term benefit. " 02/21/2015 - "Therefore, in comparison with the clinically available selective PDE3 inhibitors, MC2 has lowest metabolic side effects and might be a good candidate for treatment of congestive heart failure." 01/15/2010 - "Selective PDE3 (phosphodiesterase 3) inhibitors improve cardiac contractility and may be used in congestive heart failure. "
2.	Stroke (Strokes) 01/01/2012 - "We investigated the effects of oral preadministration of PDE3 inhibitors in a rat stroke model established by photothrombotic middle cerebral artery (MCA) occlusion. " 02/01/2022 - "Post-stroke treatment with K-134, a phosphodiesterase 3 inhibitor, improves stroke outcomes in the stroke-prone spontaneously hypertensive rat model-A comparative evaluation of antiplatelet drugs." 01/01/2020 - "Cilostazol, a phosphodiesterase 3' inhibitor, is used in Asia-Pacific countries for stroke prevention, but rarely used elsewhere. " 03/01/2016 - "Our results suggest that phosphodiesterase 3 inhibitor cilostazol may have anti-depressant effects on post-stroke depression through inhibition of neurodegeneration in the primary lesion and secondary extrafocal sites and promotion of neurogenesis. " 04/01/2001 - "Effects of olprinone, a phosphodiesterase 3 inhibitor, on regional cerebral blood flow of cerebral cortex in stroke patients."
3.	Pulmonary Hypertension 01/01/2017 - "Severe Persistent pulmonary hypertension of the newborn (PPHN) can be effectively treated with a PDE3 inhibitor as first-line treatment during neonatal transport when iNO is not readily available. " 11/01/2008 - "Milrinone, a phosphodiesterase type 3 (PDE3) inhibitor, can also reduce PVR for postoperative patients with pulmonary hypertension. " 03/01/2002 - "We have previously found that agents increasing intracellular cAMP levels of smooth muscles, such as PDE3 inhibitors, aminophylline and prostaglandin E1, produce both bronchodilation and pulmonary vasodilation in serotonin-induced pulmonary hypertension and bronchoconstriction models. " 12/01/2000 - "In the present study in dogs, we compared with aminophylline the spasmolytic effects of olprinone, a novel phosphodiesterase 3 inhibitor, on serotonin-induced pulmonary hypertension (PH) and bronchoconstriction. " 07/20/2005 - "In catheterized rabbits with acute pulmonary hypertension induced by continuous infusion of the stable thromboxane analogue U46619, we asked whether sildenafil (PDE1/5/6 inhibitor), motapizone (PDE3 inhibitor) or 8-Methoxymethyl-IBMX (PDE1 inhibitor) synergize with inhaled iloprost. "
4.	Peripheral Arterial Occlusive Disease 1 05/01/2008 - "The Cilostazol: A Study in Long-Term Effects (CASTLE) trial was a prospective randomized double-blinded trial to establish the safety of this PDE3 inhibitor use in 1435 patients with mild to moderate peripheral arterial occlusive disease. " 03/01/2023 - "Cilostazol - a phosphodiesterase 3 inhibitor - is a standard treatment for peripheral arterial occlusive disease and a potential treatment for preserving cognitive function in AD patients. " 05/01/2008 - "Cilostazol is a phosphodiesterase type 3 (PDE3) inhibitor that is effective in the treatment of symptoms of peripheral arterial occlusive disease. "
5.	Atrial Remodeling 05/01/2020 - "The purpose of this study was designed to investigate whether cilostazol, an oral phosphodiesterase 3 inhibitor (PDE3) could have protective effects on atrial remodeling in a canine model of AF and explore the potential molecular mechanisms. "

Related Drugs and Biologics

1.	Cilostazol (Pletal)
2.	Phosphoric Diester Hydrolases (Phosphodiesterases)
3.	Aspirin (Acetylsalicylic Acid)
4.	Milrinone (Primacor)
5.	Phosphodiesterase 5 Inhibitors
6.	Type 3 Cyclic Nucleotide Phosphodiesterases
7.	zaprinast
8.	olprinone
9.	Phosphodiesterase 4 Inhibitors
10.	Vasodilator Agents (Vasodilators)

Related Therapies and Procedures

1.	Therapeutics
2.	Controlled Hypotension
3.	Secondary Prevention
4.	Rewarming
5.	Stents